Core Viewpoint - The collaboration between Four Seasons Pharmaceutical and Deep Origin Biopharmaceuticals marks a significant step in the application of AI technology in the medical aesthetics sector, focusing on innovative product development and strategic positioning in the "AI + Medical Aesthetics" innovation track [1][2] Group 1: Collaboration Details - Four Seasons Pharmaceutical has signed a framework agreement with Deep Origin Biopharmaceuticals to establish an AI research and development company, aiming to explore AI-driven new medical aesthetic product development [1] - The partnership will leverage over 20 years of industry resources, commercialization pipelines, and R&D reserves from Four Seasons, while Deep Origin will provide its proprietary protein design automation platform and core technologies [1] Group 2: Technological Advancements - The collaboration aims to create a "dry-wet closed-loop" R&D platform that integrates AI design, high-throughput experimental validation, and data feedback iteration, enhancing the value of the medical aesthetics business [2] - The use of advanced generative models and large language models will shorten the early-stage R&D molecular screening cycle, reduce development costs, and improve the success rate of R&D in the medical aesthetics field [2] Group 3: Market Positioning - The focus on high-end medical aesthetic raw material innovation aims to break the dependency on imported high-end materials, promoting the upgrade of Four Seasons' medical aesthetic products towards "high-end and domestically produced" [1] - The collaboration is expected to address unmet market needs in the medical aesthetics sector, injecting momentum into the long-term development of Four Seasons' medical aesthetics business and enhancing its core competitiveness and market value [2]
四环医药拟与深原质药成立AI研发公司，共同探索AI驱动的新型医美产品开发